Olvion (Sildenafil)

Sildenafil, the active ingredient in Olvion, is a phosphodiesterase type 5 (PDE5) inhibitor presented as a tablet for oral use. It treats erectile dysfunction in adult males and is also prescribed for pulmonary arterial hypertension in specific patient groups. GNH USA supplies Olvion as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Olvion as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Sildenafil acts on the nitric‑oxide/cGMP pathway to improve blood flow in conditions where vascular relaxation is therapeutic.

- Erectile dysfunction: improves ability to achieve and maintain an erection suitable for sexual activity. - Pulmonary arterial hypertension: lowers pulmonary arterial pressure and improves exercise capacity. - Secondary Raynaud’s phenomenon: reduces frequency and severity of vasospastic attacks.

Sildenafil may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache - Flushing - Dyspepsia - Nasal congestion - Visual disturbances (blurred vision, colour tinge) - Myalgia

Serious or Rare Side Effects: - Sudden loss of vision (non‑arteritic anterior ischemic optic neuropathy) - Sudden hearing loss - Prolonged erection lasting more than 4 hours (priapism) - Severe hypotension - Cardiac arrhythmia

When using Sildenafil, certain precautions should be observed to ensure safe and effective therapy.

- Cardiovascular assessment: evaluate underlying heart disease before initiating therapy. - Concomitant nitrate use: avoid due to risk of severe hypotension. - Visual disorders: discontinue if sudden vision loss occurs. - Hearing changes: monitor for sudden hearing loss. - Drug interactions: review all concurrent medications for potential interactions. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture and direct sunlight.

Sildenafil can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Nitrates (e.g., nitroglycerin): may cause profound hypotension. - Guanylate cyclase stimulators (e.g., riociguat): risk of excessive vasodilation. - Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase sildenafil exposure.

Moderate Interactions (Monitor Closely): - Alpha‑blockers: may enhance blood pressure lowering effects. - Antihypertensives: additive hypotensive effect possible. - Protease inhibitors (e.g., ritonavir): may raise plasma levels modestly.